Claims
- 1. A complex formed by reacting technetium-99m and a reducing agent with a reagent comprising
- a) a peptide that specifically binds to a target in vivo; and
- b) a radiolabel binding moiety covalently linked to the peptide; wherein the complex between said technetium-99m and said moiety is electrically neutral, avoiding interference by the complex with specific binding of the peptide to the target.
- 2. The complex of claim 1, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion, and a ferrous ion.
- 3. A complex formed by labeling a reagent comprising
- a) a peptide that specifically binds to a target in vivo; and
- b) a radiolabel binding moiety covalently linked to the peptide; with technetium-99m by ligand exchange of a prereduced technetium-99m complex, wherein the complex between said technetium-99m and said moiety is electrically neutral, avoiding interference by the complex with specific binding of the pettide to the target.
- 4. The complex of claims 1, 2, or 3, wherein the moiety has a formula selected from the group consisting of: ##STR8## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ; each (pgp).sup.s is independently a thiol protecting group or H;
- m, n and p are independently 2 or 3;
- A=linear or cyclic lower alkyl, aryl, heterocyclyl, a combination thereof;
- X=a bond covalently linking the moiety to the peptide;
- and ##STR9## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ; m, n and p are independently 2 or 3;
- A=linear or cyclic lower alkyl, aryl, heterocyclyl, a combination thereof;
- V=H or --CO-X;
- R'=H or X;
- X=a bond covalently linking the moiety to the peptide;
- and wherein when V=H, R'=peptide and when R'=H, V=--CO-peptide.
- 5. The complex of claims 1, 2, or 3, wherein the peptide is selected from the group consisting of:
- formyl-MLF;
- (VGVAPG).sub.3 amide;
- (VPGVG).sub.4 amide;
- RALVDTLKFVTQAEGAKamide (SEQ ID NO: 1);
- RALVDTEFKVKQEAGAKamide (SEO ID NO: 2):
- PLARITLPDFRLPEIAIPamide (SEQ ID NO: 3);
- GQQHHLGGAKAGDV (SEQ ID NO: 4);
- PLYKKIIKKLLES (SEQ ID NO: 5);
- LRALVDTLKamide (SEQ ID NO: 6);
- GGGLRALVDTLKamide (SEQ ID NO: 7);
- GGGLRALVDTLKFVTQAEGAKamide (SEQ ID NO: 8);
- GGGRALVDTLKALVDTLamide (SEQ ID NO: 9);
- GHRPLDKKREEAPSLRPAPPPISGGGYR (SEQ ID NO: 10);
- PSPSPIHPAHHKRDRRQamide (SEQ ID NO: 11);
- GGGF.sub.D.Cpa.YW.sub.D KTFTamide; ##STR10## {SYNRGDSTC(S-maleimido)CH.sub.2 CH.sub.2 -}.sub.3 N]GCGGGLRALVDTLKamide (SEQ ID NO: 13);
- GCYRALVDTLKFVTQAEGAKamide (SEQ ID NO: 14); and
- GC(VGVAPG).sub.3 amide.
- 6. A method for imaging a site within a mammalian body comprising the steps of administering an effective diagnostic amount of the complex of claims 1, 2 or 3, and detecting the technetium-99m localized at the site.
- 7. A method for imaging a site within a mammalian body comprising the steps of administering an effective diagnostic amount of the complex of claim 5, and detecting the technetium-99m localized at the site.
- 8. An electrically neutral complex formed between technetium-99m and a radiolabel-binding moiety covalently linked to a peptide having specific binding properties, wherein interference with said properties by said complex is avoided.
Parent Case Info
This application is a continuation-in-part of U.S. Ser. No. 07/851,074, now abandoned filed Mar. 13, 1992, the disclosure of which is hereby incorporated by reference.
US Referenced Citations (17)
Foreign Referenced Citations (1)
Number |
Date |
Country |
063002 |
Oct 1982 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
851074 |
Mar 1992 |
|